专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004070010A2 A METHOD FOR GENERATING HIGH AFFINITY ANTIBODIES 审中-公开
标题翻译：一种产生高亲属抗体的方法
公开(公告)号：WO2004070010A2
公开(公告)日：2004-08-19
申请号：PCT/US2004/002892
申请日：2004-02-02
申请人： TANOX, INC. , SINGH, Sanjaya , FOSTER, Catherine , WU, Herren
发明人： SINGH, Sanjaya , FOSTER, Catherine , WU, Herren
IPC分类号： C12N
CPC分类号： C07K16/18 , C07K16/005 , C07K16/4291 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N2800/24 , Y10S435/81
摘要： The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译：本发明涉及高亲和力的人单克隆抗体，特别是针对免疫球蛋白E（IgE）的同种型决定簇的那些，以及这些抗体的直接等同物和衍生物。这些抗体以比原始亲本抗体大至少100倍的亲和力结合到它们各自的靶。这些抗体可用于疾病的诊断，预防和治疗。

2. 发明申请

WO2004070011A2 HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES 审中-公开
标题翻译：高亲属抗人IgE抗体
公开(公告)号：WO2004070011A2
公开(公告)日：2004-08-19
申请号：PCT/US2004/002894
申请日：2004-02-02
申请人： TANOX, INC. , SINGH, Sanjaya , FOSTER, Catherine , WU, Herren
发明人： SINGH, Sanjaya , FOSTER, Catherine , WU, Herren
IPC分类号： C12N
CPC分类号： C07K16/18 , C07K16/005 , C07K16/4291 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N2800/24 , Y10S435/81
摘要： The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译：本发明涉及高亲和力的人单克隆抗体，特别是针对免疫球蛋白E（IgE）的同种型决定簇的那些，以及这些抗体的直接等同物和衍生物。这些抗体以比原始亲本抗体大至少100倍的亲和力结合到它们各自的靶。这些抗体可用于疾病的诊断，预防和治疗。

3. 发明申请

WO2008055206A2 HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：人类抗因子D抗体及其用途
公开(公告)号：WO2008055206A2
公开(公告)日：2008-05-08
申请号：PCT/US2007/083172
申请日：2007-10-31
申请人： GENENTECH, INC. , WU, Herren , SINGH, Sanjaya , FUNG, Sek, Chung , AN, Ling-ling , LOWMAN, Henry, B. , KELLEY, Robert, F.
发明人： WU, Herren , SINGH, Sanjaya , FUNG, Sek, Chung , AN, Ling-ling , LOWMAN, Henry, B. , KELLEY, Robert, F.
IPC分类号： C07K16/36 , A61P37/00 , A61P27/02
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译：本发明涉及人源化抗人因子D单克隆抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其在制备用于治疗与过度或不受控制的疾病和病症的组合物和药物中的用途补体激活。这些抗体可用于疾病的诊断，预防和治疗。

4. 发明申请

WO2003035695A2 AGENTS THAT ACTIVATE OR INHIBIT TOLL-LIKE RECEPTOR 9 审中-公开
标题翻译：激活或抑制类似感受器的药剂9
公开(公告)号：WO2003035695A2
公开(公告)日：2003-05-01
申请号：PCT/US2002/023645
申请日：2002-07-25
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C07K16/00
CPC分类号： C07K16/28 , A61K2039/505 , A61K2039/55516 , A61K2039/55561
摘要： The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255 Cys-Arg-Arg 2 58 Cys (as CRRC) or at 265 Cys-Met-GIu 2 68 Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.
摘要翻译：本发明包括与TLR9上的肽段结合并模拟CpG基序的作用的分子。 CpG模拟剂包括但不限于抗体，小分子化合物，肽，肽模拟物和核酸，包括组合物，其包含结合TLR9上的肽段的分子，并模拟适合于给予需要治疗的患者，任选地与例如赋形剂，稀释剂或载体组合。此外，本发明包括在255Cys-Arg-Arg 258Cys作为CRRC或作为CMEC的265Cys-Met-Glu 268Cys与TLR9的CXXC基序结合的那些分子。本发明包括通过诱导Th1型应答来调节免疫应答的方法，包括施用结合TLR9并模拟CpG功能的分子。这些分子也将宿主细胞反应从Th2型反应转移到Th1型反应。因此，施用结合TLR9的本发明的分子可以避免Th2介导的免疫诱导的过敏反应的风险，使得该方法可用于免疫治疗和哮喘治疗。本发明的分子可以与特定的变应原组合施用。

5. 发明申请

WO2002102320A3 FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA 审中-公开
公开(公告)号：WO2002102320A3
公开(公告)日：2002-12-27
申请号：PCT/US2002/019448
申请日：2002-06-14
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C12N15/00
摘要： The present invention includes Fcε fragments conjugated with FCγ fragments, for example, Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCγ ; FCε2-Fcε3- Fcγ; FCε3-Fcγ; and FCε3-Fcε4-FCγ , or any derivative or peptide, which has equivalent immunological function. The Fcγ fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.

6. 发明申请

WO2002102320A2 FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA 审中-公开
标题翻译： FCE融合蛋白治疗过敏和哮喘
公开(公告)号：WO2002102320A2
公开(公告)日：2002-12-27
申请号：PCT/US2002/019448
申请日：2002-06-14
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： A61K
CPC分类号： C07K16/00 , A61K2039/505 , C07K2317/52 , C07K2319/00
摘要： The present invention includes Fcε fragments conjugated with FCγ fragments, for example, Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCγ ; FCε2-Fcε3- Fcγ; FCε3-Fcγ; and FCε3-Fcε4-FCγ , or any derivative or peptide, which has equivalent immunological function. The Fcγ fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.
摘要翻译：本发明包括与FCγ片段缀合的Fcε片段，例如Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; 铰链FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCγ; FC epsilon 2-Fcε3-Fcγ; FC epsilon 3-Fcγ; 和FCε3-Fcε4-FCγ或具有相同免疫功能的任何衍生物或肽。 Fcγ片段可以是IgG亚类（IgG1I IgG2，IgG3或IgG4），优选IgG1或IgG3中任一种的片段，其中片段结合FcyRIIB。本发明还包括适用于在包含例如赋形剂，稀释剂或载体的药物组合物中给患有包含融合蛋白构建体的过敏性疾病患者施用的组合物。该治疗可以与抗IgE治疗或变应原免疫治疗组合。

7. 发明申请

WO2003035695A3 AGENTS THAT ACTIVATE OR INHIBIT TOLL-LIKE RECEPTOR 9 审中-公开
公开(公告)号：WO2003035695A3
公开(公告)日：2003-05-01
申请号：PCT/US2002/023645
申请日：2002-07-25
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C07K16/28
摘要： The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255 Cys-Arg-Arg 2 58 Cys (as CRRC) or at 265 Cys-Met-GIu 2 68 Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.

8. 发明申请

WO2008100816A9 ANTIBODY LIBRAY DISPLAY BY YEAST CELL PLASMA MEMBRANE 审中-公开
公开(公告)号：WO2008100816A9
公开(公告)日：2008-08-21
申请号：PCT/US2008/053398
申请日：2008-02-08
申请人： MEDIMMUNE, LLC , WU, Herren , GAO, Changshou
发明人： WU, Herren , GAO, Changshou
IPC分类号： A61K39/00 , C12N1/00
摘要： The present invention relates to antibodies or antibody fragments that may be displayed on the extracellular surface of the plasma membrane when expressed in a host cell. The present invention provides libraries comprising a plurality of plasma membrane displayed antibodies and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.

9. 发明申请

WO2008031056A2 HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE 审中-公开
标题翻译：人源化抗CD19抗体及其在治疗肿瘤，移植和自身免疫性疾病中的应用
公开(公告)号：WO2008031056A2
公开(公告)日：2008-03-13
申请号：PCT/US2007/077916
申请日：2007-09-07
申请人： MEDIMMUNE, INC. , DAMSCHRODER, Melissa , KIENER, Peter , WU, Herren , DALL'ACQUA, William , HERBST, Ronald , COYLE, Anthony
发明人： DAMSCHRODER, Melissa , KIENER, Peter , WU, Herren , DALL'ACQUA, William , HERBST, Ronald , COYLE, Anthony
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
摘要： The present invention provides chimeric and humanized versions of anti-CD 19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD 19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft- versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
摘要翻译：本发明提供了抗CD 19小鼠单克隆抗体的嵌合和人源化形式。本发明进一步涉及使用治疗性抗体的药物组合物，免疫治疗组合物和方法，所述治疗性抗体结合人CD 19抗原并可介导ADCC，CDC和/或细胞凋亡以治疗B细胞疾病和病症，例如但不限于不限于B细胞恶性肿瘤，用于治疗和预防自身免疫性疾病，以及用于治疗和预防人移植受体中移植物抗宿主病（GVHD），体液排斥和移植后淋巴增殖性疾病。 p>

10. 发明申请

WO2007084253A2 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
标题翻译： HMGB1的高亲和力抗体及其使用方法
公开(公告)号：WO2007084253A2
公开(公告)日：2007-07-26
申请号：PCT/US2006/061258
申请日：2006-11-27
申请人： MEDIMMUNE, INC. , CRITICAL THERAPEUTICS , WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , MAO, Su-yau , COYLE, Anthony , TIAN, Jane , O'KEEFE, Theresa , QIN, Shixin
发明人： WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , MAO, Su-yau , COYLE, Anthony , TIAN, Jane , O'KEEFE, Theresa , QIN, Shixin
IPC分类号： A61K39/395 , C07K16/40
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/32
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
摘要翻译：公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血症，内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。此外，本发明的高亲和力抗体可用作诊断抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式